AAPL335.29+8.72 (+2.67%) ▲|ABBV256.43+1.43 (+0.56%) ▲|ABT101.74-1.62 (-1.57%) ▼|ACN180.17+2.26 (+1.27%) ▲|ADBE248.03-0.80 (-0.32%) ▼|AMAT463.70+9.69 (+2.13%) ▲|AMD517.08+13.48 (+2.68%) ▲|AMGN379.96-2.52 (-0.66%) ▼|AMT178.28+5.30 (+3.06%) ▲|AMZN255.90+4.01 (+1.59%) ▲|AVGO365.67+4.84 (+1.34%) ▲|AXP323.95+3.24 (+1.01%) ▲|BA209.03+4.23 (+2.07%) ▲|BAC62.77+0.21 (+0.34%) ▲|BKNG173.69-0.22 (-0.13%) ▼|BLK1,086.15+23.75 (+2.24%) ▲|BMY63.33-0.42 (-0.66%) ▼|BNY162.95+0.36 (+0.22%) ▲|BRK-B506.99-0.01 (0.00%) ▼|C138.49-0.01 (-0.01%) ▼|CAT821.43+16.43 (+2.04%) ▲|CL87.17-0.73 (-0.83%) ▼|CMCSA25.26+0.09 (+0.34%) ▲|COF207.32+0.21 (+0.10%) ▲|COP136.06-0.98 (-0.72%) ▼|COST903.31+0.93 (+0.10%) ▲|CRM248.33+5.33 (+2.19%) ▲|CSCO111.88+4.44 (+4.13%) ▲|CVS94.04-1.26 (-1.32%) ▼|CVX213.71+0.95 (+0.44%) ▲|DE685.84+7.90 (+1.17%) ▲|DHR200.47-0.07 (-0.03%) ▼|DIS106.92+1.10 (+1.04%) ▲|DUK119.38+0.01 (+0.01%) ▲|EMR150.99+2.62 (+1.77%) ▲|FDX311.14-0.66 (-0.21%) ▼|GD354.17-0.09 (-0.02%) ▼|GE323.91-0.25 (-0.08%) ▼|GEV951.57+27.66 (+2.99%) ▲|GILD143.66-1.15 (-0.79%) ▼|GM85.96-0.16 (-0.19%) ▼|GOOG338.74+8.35 (+2.53%) ▲|GOOGL341.70+9.10 (+2.74%) ▲|GS1,028.20+8.43 (+0.83%) ▲|HD309.33+3.64 (+1.19%) ▲|HON202.77+0.59 (+0.29%) ▲|IBM238.28+4.26 (+1.82%) ▲|INTC103.53+3.21 (+3.20%) ▲|INTU318.93+6.16 (+1.97%) ▲|ISRG367.64+7.18 (+1.99%) ▲|JNJ266.62+0.27 (+0.10%) ▲|JPM356.65+3.09 (+0.87%) ▲|KO88.00+0.17 (+0.19%) ▲|LIN464.70+3.08 (+0.67%) ▲|LLY1,120.39-2.62 (-0.23%) ▼|LMT524.42-5.71 (-1.08%) ▼|LOW197.49+0.90 (+0.46%) ▲|LRCX301.58+3.57 (+1.20%) ▲|MA567.37+2.00 (+0.35%) ▲|MCD252.95-0.10 (-0.04%) ▼|MDLZ62.27-0.20 (-0.32%) ▼|MDT90.38-1.24 (-1.35%) ▼|META653.25+8.87 (+1.38%) ▲|MMM163.88+1.02 (+0.62%) ▲|MO68.84+0.05 (+0.07%) ▲|MRK144.37-0.34 (-0.24%) ▼|MS213.45+0.79 (+0.37%) ▲|MSFT496.15+3.71 (+0.75%) ▲|MU978.44+1.03 (+0.11%) ▲|NEE82.37-0.07 (-0.08%) ▼|NFLX76.84+0.83 (+1.09%) ▲|NKE36.89+0.27 (+0.74%) ▲|NOW131.74+0.57 (+0.43%) ▲|NVDA219.95+1.59 (+0.73%) ▲|ORCL153.28+0.34 (+0.22%) ▲|PEP136.71+0.06 (+0.04%) ▲|PFE27.44-0.22 (-0.78%) ▼|PG144.00+1.03 (+0.72%) ▲|PLTR166.84+0.98 (+0.59%) ▲|PM193.05+3.28 (+1.73%) ▲|QCOM184.30+7.42 (+4.19%) ▲|RTX197.50-0.62 (-0.31%) ▼|SBUX99.47+0.25 (+0.25%) ▲|SCHW106.44-0.89 (-0.83%) ▼|SO87.92+0.17 (+0.19%) ▲|SPG204.94+0.27 (+0.13%) ▲|T26.26+0.71 (+2.76%) ▲|TMO611.59+8.41 (+1.39%) ▲|TMUS183.07+5.91 (+3.34%) ▲|TSLA365.57+2.01 (+0.55%) ▲|TXN272.07+13.25 (+5.12%) ▲|UBER71.32-1.24 (-1.71%) ▼|UNH378.87-9.41 (-2.42%) ▼|UNP284.48-1.31 (-0.46%) ▼|UPS99.71-0.26 (-0.26%) ▼|USB62.69+0.28 (+0.44%) ▲|V370.08+2.87 (+0.78%) ▲|VZ50.68+0.71 (+1.42%) ▲|WFC90.27+0.82 (+0.92%) ▲|WMT106.20+0.47 (+0.44%) ▲|XOM165.53+0.30 (+0.18%) ▲|AAPL335.29+8.72 (+2.67%) ▲|ABBV256.43+1.43 (+0.56%) ▲|ABT101.74-1.62 (-1.57%) ▼|ACN180.17+2.26 (+1.27%) ▲|ADBE248.03-0.80 (-0.32%) ▼|AMAT463.70+9.69 (+2.13%) ▲|AMD517.08+13.48 (+2.68%) ▲|AMGN379.96-2.52 (-0.66%) ▼|AMT178.28+5.30 (+3.06%) ▲|AMZN255.90+4.01 (+1.59%) ▲|AVGO365.67+4.84 (+1.34%) ▲|AXP323.95+3.24 (+1.01%) ▲|BA209.03+4.23 (+2.07%) ▲|BAC62.77+0.21 (+0.34%) ▲|BKNG173.69-0.22 (-0.13%) ▼|BLK1,086.15+23.75 (+2.24%) ▲|BMY63.33-0.42 (-0.66%) ▼|BNY162.95+0.36 (+0.22%) ▲|BRK-B506.99-0.01 (0.00%) ▼|C138.49-0.01 (-0.01%) ▼|CAT821.43+16.43 (+2.04%) ▲|CL87.17-0.73 (-0.83%) ▼|CMCSA25.26+0.09 (+0.34%) ▲|COF207.32+0.21 (+0.10%) ▲|COP136.06-0.98 (-0.72%) ▼|COST903.31+0.93 (+0.10%) ▲|CRM248.33+5.33 (+2.19%) ▲|CSCO111.88+4.44 (+4.13%) ▲|CVS94.04-1.26 (-1.32%) ▼|CVX213.71+0.95 (+0.44%) ▲|DE685.84+7.90 (+1.17%) ▲|DHR200.47-0.07 (-0.03%) ▼|DIS106.92+1.10 (+1.04%) ▲|DUK119.38+0.01 (+0.01%) ▲|EMR150.99+2.62 (+1.77%) ▲|FDX311.14-0.66 (-0.21%) ▼|GD354.17-0.09 (-0.02%) ▼|GE323.91-0.25 (-0.08%) ▼|GEV951.57+27.66 (+2.99%) ▲|GILD143.66-1.15 (-0.79%) ▼|GM85.96-0.16 (-0.19%) ▼|GOOG338.74+8.35 (+2.53%) ▲|GOOGL341.70+9.10 (+2.74%) ▲|GS1,028.20+8.43 (+0.83%) ▲|HD309.33+3.64 (+1.19%) ▲|HON202.77+0.59 (+0.29%) ▲|IBM238.28+4.26 (+1.82%) ▲|INTC103.53+3.21 (+3.20%) ▲|INTU318.93+6.16 (+1.97%) ▲|ISRG367.64+7.18 (+1.99%) ▲|JNJ266.62+0.27 (+0.10%) ▲|JPM356.65+3.09 (+0.87%) ▲|KO88.00+0.17 (+0.19%) ▲|LIN464.70+3.08 (+0.67%) ▲|LLY1,120.39-2.62 (-0.23%) ▼|LMT524.42-5.71 (-1.08%) ▼|LOW197.49+0.90 (+0.46%) ▲|LRCX301.58+3.57 (+1.20%) ▲|MA567.37+2.00 (+0.35%) ▲|MCD252.95-0.10 (-0.04%) ▼|MDLZ62.27-0.20 (-0.32%) ▼|MDT90.38-1.24 (-1.35%) ▼|META653.25+8.87 (+1.38%) ▲|MMM163.88+1.02 (+0.62%) ▲|MO68.84+0.05 (+0.07%) ▲|MRK144.37-0.34 (-0.24%) ▼|MS213.45+0.79 (+0.37%) ▲|MSFT496.15+3.71 (+0.75%) ▲|MU978.44+1.03 (+0.11%) ▲|NEE82.37-0.07 (-0.08%) ▼|NFLX76.84+0.83 (+1.09%) ▲|NKE36.89+0.27 (+0.74%) ▲|NOW131.74+0.57 (+0.43%) ▲|NVDA219.95+1.59 (+0.73%) ▲|ORCL153.28+0.34 (+0.22%) ▲|PEP136.71+0.06 (+0.04%) ▲|PFE27.44-0.22 (-0.78%) ▼|PG144.00+1.03 (+0.72%) ▲|PLTR166.84+0.98 (+0.59%) ▲|PM193.05+3.28 (+1.73%) ▲|QCOM184.30+7.42 (+4.19%) ▲|RTX197.50-0.62 (-0.31%) ▼|SBUX99.47+0.25 (+0.25%) ▲|SCHW106.44-0.89 (-0.83%) ▼|SO87.92+0.17 (+0.19%) ▲|SPG204.94+0.27 (+0.13%) ▲|T26.26+0.71 (+2.76%) ▲|TMO611.59+8.41 (+1.39%) ▲|TMUS183.07+5.91 (+3.34%) ▲|TSLA365.57+2.01 (+0.55%) ▲|TXN272.07+13.25 (+5.12%) ▲|UBER71.32-1.24 (-1.71%) ▼|UNH378.87-9.41 (-2.42%) ▼|UNP284.48-1.31 (-0.46%) ▼|UPS99.71-0.26 (-0.26%) ▼|USB62.69+0.28 (+0.44%) ▲|V370.08+2.87 (+0.78%) ▲|VZ50.68+0.71 (+1.42%) ▲|WFC90.27+0.82 (+0.92%) ▲|WMT106.20+0.47 (+0.44%) ▲|XOM165.53+0.30 (+0.18%) ▲|
23.1 C
New York
Friday, September 11, 2026

Tag: study

newssourceFORcompanyinformationcontent1releasesmarket

ArkBio’s New Drug Application for ADHD Therapeutic Azstarys Accepted and Granted Priority Review by China NMPA

SHANGHAI, June 15, 2025 /PRNewswire/ -- Shanghai Ark Biopharmaceutical Co., Ltd. ("ArkBio") today announced that the National Medical Products Administration (NMPA) has officially accepted...

Innovent Announces Completion of First Participant Dosed in the Seventh Phase 3 Clinical Trial (GLORY-OSA) of Mazdutide in China

SAN FRANCISCO and SUZHOU, China, June 15, 2025 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes...

Celltrion announces U.S. FDA approval of additional presentation of STEQEYMA® (ustekinumab-stba), expanding dosing options for pediatric patients

Approval of 45mg/0.5mL solution in a single-dose vial for subcutaneous injection expands dosing flexibility for pediatric patients with plaque psoriasis (PsO) or psoriatic arthritis...

EHA 2025 | Multiple Studies Report Encouraging Data of Olverembatinib in Ph+ ALL

ROCKVILLE, Md. and SUZHOU, China, June 15, 2025 (GLOBE NEWSWIRE) -- Ascentage Pharma (NASDAQ: AAPG; HKEX: 6855), a global biopharmaceutical company dedicated to addressing unmet medical needs in cancers, announced that results from 13 studies of its core assets, including the novel drug olverembatinib (HQP1351) and the investigational EED inhibitor APG-5918, have been reported at the 2025 European Hematology Association (EHA) Annual Congress.

Press Release: EAACI: Dupixent demonstrated superiority over Xolair (omalizumab) in chronic rhinosinusitis with nasal polyps in patients with coexisting asthma in first-ever presented phase...

EAACI: Dupixent demonstrated superiority over Xolair (omalizumab) in chronic rhinosinusitis with nasal polyps in patients with coexisting asthma in first-ever presented phase 4 head-to-head respiratory study

Dupixent® (dupilumab) Demonstrated Superiority Over Xolair® (Omalizumab) in Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) in Patients with Coexisting Asthma in First-ever Presented Phase 4...

New late-breaking data at EAACI showed Dupixent outperformed Xolair across all primary and secondary efficacy endpoints of CRSwNP and in all asthma-related endpoints

Intellia Therapeutics Announces Positive Three-Year Data from Phase 1 Trial of Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema (HAE) at the European Academy...

CAMBRIDGE, Mass., June 15, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced three-year follow-up data from the Phase 1 portion of the ongoing Phase 1/2 study in patients with HAE after receiving a single dose of lonvoguran ziclumeran (lonvo-z, also known as NTLA-2002). Results were shared in an oral presentation at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2025, held June 13-16 in Glasgow, United Kingdom.

Airbus and McGill University are driving innovation in aerospace with an agreement for experiential learning and research

The initiative will help further propel Quebec and Canadian aerospace on the world stage, thus strengthening Montréal's position as one of the major international...

Genmab Announces Epcoritamab Investigational Combination Therapy Demonstrates High Response Rates in Patients with Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) Eligible for...

Media Release

COPENHAGEN, Denmark; June 15, 2025

Investigational combination of first-in-class bispecific antibodies TALVEY®▼ (talquetamab) and TECVAYLI®▼ (teclistamab) shows deep and durable responses in heavily pretreated multiple myeloma patients with extramedullary...

Results from the Phase 2 RedirecTT-1 study demonstrate deep responses with 78.9 percent overall response rate through dual targeting of GPRC5D and BCMA1 

Investigational combination of first-in-class bispecifics TALVEY® and TECVAYLI® shows deep and durable responses in heavily pretreated multiple myeloma patients with extramedullary disease

Results from the Phase 2 RedirecTT-1 study demonstrate deep responses with 78.9 percent overall response rate through dual targeting of GPRC5D and BCMA Data signal...

[Ad hoc announcement pursuant to Art. 53 LR] Roche provides safety update on Elevidys™ gene therapy for Duchenne muscular dystrophy in non-ambulatory patients

Basel, 15 June 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today new dosing restrictions, effective immediately, for ELEVIDYS™ (delandistrogene moxeparvovec), for non-ambulatory Duchenne muscular dystrophy (DMD) patients, irrespective of age, in both clinical and commercial settings. In the commercial setting, non-ambulatory patients should no longer receive Elevidys. In the clinical trial setting, enrolment and dosing of non-ambulatory patients will be immediately paused until additional risk mitigation measures (e.g. immune modulatory treatment) are implemented in the study protocol. Health authorities, investigators and physicians are being informed so that patient care can be quickly adjusted.

FOX NEWS CHANNEL’S BRET BAIER LANDS FIRST INTERVIEW WITH ISRAELI PRIME MINISTER BENJAMIN NETANYAHU SINCE ISRAEL’S STRIKES ON IRAN ON SUNDAY, JUNE 15TH

NEW YORK, June 14, 2025 /PRNewswire/ -- FOX News Channel's Bret Baier will present a worldwide exclusive live interview with Israeli Prime Minister Bibi Netanyahu on...

ROSEN, GLOBAL INVESTOR COUNSEL, Encourages PepGen Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – PEPG

NEW YORK, June 14, 2025 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of securities of PepGen Inc. (NASDAQ: PEPG) between March 7, 2024 and March 3, 2025, both dates inclusive (the “Class Period”). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than August 8, 2025.

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsStudy

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers